ArticleFrontiers in oncology2022

Case Report: Outcome and Adverse Events of Anti-PD-1 Antibody Plus Chidamide for Relapsed/Refractory Sézary Syndrome: Case Series and A Literature Review.

Chao Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.